Effects of Escitalopram on Anxiety in Patients with Acute Coronary Syndrome: A Randomized Controlled Trial
Clinical Psychopharmacology and Neuroscience
;
: 126-131, 2017.
Article
Dans Anglais
| WPRIM
| ID: wpr-203970
ABSTRACT
OBJECTIVE:
There are no evidence-based practices for treating anxiety in patients with acute coronary syndrome (ACS). Thus, we investigated the effects of escitalopram on anxiety in this population.METHODS:
We enrolled 217 patients with ACS who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for depressive disorders into a randomized double-blind placebo-controlled study. Patients received either escitalopram or placebo over a 24-week period. Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A). A HADS-A score >7 was classified as an anxiety disorder. Baseline evaluations included sociodemographic and clinical characteristics, such as depressive symptoms, cardiovascular risk factors, and current cardiac status.RESULTS:
Independent of improvements in depression and without any differences in safety profiles, escitalopram treatment was significantly more efficacious in treating and reducing anxiety than placebo over a 24-week period.CONCLUSION:
Escitalopram can be recommended as an effective and safe treatment option for anxiety in patients with ACS.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anxiété
/
Troubles anxieux
/
Citalopram
/
Méthode en double aveugle
/
Facteurs de risque
/
Diagnostic and stastistical manual of mental disorders (USA)
/
Dépression
/
Trouble dépressif
/
Syndrome coronarien aigu
Type d'étude:
Essai clinique contrôlé
/
Etude d'étiologie
/
Guide de pratique
/
Facteurs de risque
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Clinical Psychopharmacology and Neuroscience
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS